Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer

Gastric Cancer. Clinical Trial

Status Available

Clinical Trial Summary

• To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin/5-fluorouracil) as first-line treatment for advanced gastric cancer

• The design of the study incorporated a standard 3 + 3 dose escalation procedure to guide elevation of the sorafenib dosage to the next level

Clinical Trial Description

-Twice-daily dosing of sorafenib 200 mg in combination with FOLFOX4 proved effective and safe for the treatment of advanced gastric cancer. ;

Study Design

N/A

Related Conditions & MeSH terms

• Gastric Cancer.
• Stomach Neoplasms

• NCT number: NCT02209441
• Study type: Expanded Access
• Source: Chinese Academy of Medical Sciences
• Contact: Yihebali Chi, Doctor
• Phone: +86 13911075626
• Email: yihebalichi@hotmail.com
• Status: Available
• Phase: N/A